European Medicines Agency On The Cusp Of Saying No To Aduhelm, Impacting Millions Of Alzheimer’s Patients

Washington, D.C. -- The European Medicines Agency (EMA) appears poised to determine that Aduhelm, the only treatment on the market that modifies the course of Alzheimer’s and the only treatment approved in the United States in nearly 20 years, should not be approved for treating people in Europe. If the EMA does this in its December meeting, it would be a devastating blow to millions of European patients and their loved ones, and a short-sighted decision that will prove harmful in the fight against Alzheimer’s.

“Aduhelm is more than a treatment – it offers hope to millions of Alzheimer’s patients. The negative leaning reflected in the potential decision by the EMA reported in the press today is hugely disappointing. If the EMA proceeds in this direction, the agency would take away hope while eliminating access to a medication that can benefit many Europeans who are otherwise facing inevitable decline, dependence and death,” said George Vradenburg, chair and co-founder of UsAgainstAlzheimer’s. “Aduhelm is also spurring further medical innovation in the fight against Alzheimer’s, but with a negative decision the EMA would send a clear message: the door to innovation may be open in the United States but not in Europe; don’t even try.”

Alzheimer’s has catastrophic consequences. Now is the time to treat this disease as the emergency it is and commit to ending it, rather than take away hope by saying no to a treatment that is already helping people.


About UsAgainstAlzheimer’s

UsAgainstAlzheimer’s exists to conquer Alzheimer’s disease. We take on the toughest problems; bring all of “Us” together to break down barriers; advocate for research that will speed treatments to market; and drive changes that matter most to people living with the disease. We will not rest until brain-span equals lifespan - for everyone.